Who is eligible for clinical trial NCT07006792?

Participants must meet protocol criteria for Atopic Dermatitis. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07006792 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-05-21

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden (NCT07006792)

🔵 Active, Not Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: Eli Lilly and Company

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (21 items).

Location: Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology — Birmingham, Alabama

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Have chronic atopic dermatitis (AD) (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before screening visit.
Have 10% to 25% body surface area (BSA) of AD involvement at screening and baseline.
Have pruritus numeric rating scale (NRS) ≥6 at baseline.
Have an Eczema Area and Severity Index (EASI) score ≥16 at screening and baseline.
Have an Investigator's Global Assessment (IGA) score ≥3 (on a scale of 0 to 4) at screening and baseline.
Based on investigator judgement, have a history of inadequate response to treatment with topical medications, or determination that topical treatments are otherwise medically inadvisable.
For participants aged 12 to less than 18, have a body weight ≥40 kilograms (kg) at baseline.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Have an uncontrolled chronic disease that might require multiple intermittent uses of oral corticosteroids at screening (as defined by the investigator).
Have known liver cirrhosis and/or chronic hepatitis of any etiology.
History of malignancy, including mycosis fungoides or cutaneous T-cell lymphoma, within 5 years before the screening, except completely treated in situ carcinoma of the cervix of completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin with no evidence of recurrence in the past 12 weeks.
Are diagnosed with active endoparasitic infections or at high risk of these infections.
Have a known or suspected history of immunosuppression, including history of invasive opportunistic infections despite infection resolution; or unusually frequent, recurrent, or prolonged infections, per the investigator's judgment.
Have presence of skin comorbidities that may interfere with study assessments.
Have a severe concomitant illness(es) that in the investigator's judgment would adversely affect the participant's participation in the study.
Have had any of the following types of infection within 3 months of screening or develop any of these infections during screening:
Serious (requiring hospitalization, and/or intravenous or equivalent oral antibiotic treatment).
Opportunistic - Note: Herpes zoster is considered active and ongoing until all vesicles are dry and crusted over.
Chronic (duration of symptoms, signs, and/or treatment of 6 weeks or longer).

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (66 Sites)

Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology — Birmingham, Alabama
Research Solutions of Arizona — Litchfield Park, Arizona
Alliance Dermatology and Mohs Center — Phoenix, Arizona
California Dermatology & Clinical Research Institute — Encinitas, California
Dermatology Research Associates — Los Angeles, California
NorCal Clinical Research — Rocklin, California
Suncoast Research Associates — Doral, Florida
Encore Medical Research — Hollywood, Florida
Solutions Through Advanced Research — Jacksonville, Florida
Life Arc Research Centers - Miami — Miami, Florida
MCR Research — Miami, Florida
Health Clinical Research — Miami, Florida
Deluxe Health Center — Miami Lakes, Florida
Renstar Medical Research — Ocala, Florida
Leading Edge Dermatology — Plantation, Florida
Dermatology Affiliates Research Institute — Atlanta, Georgia
DeNova Research — Chicago, Illinois
Southern Indiana Clinical Research Center — Columbus, Indiana
Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana
Southern Indiana Clinical Trials — New Albany, Indiana
Equity Medical - Bowling Green — Bowling Green, Kentucky
Allergy & Asthma Specialists, P.S.C. — Owensboro, Kentucky
Foxhall Research Center — Chevy Chase, Maryland
Great Lakes Research Group, Inc. — Bay City, Michigan
Revival Research Institute, LLC — Troy, Michigan

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗